What is VIP nasal spray, and does it work for CIRS or mold illness?

The short answer

VIP is an anti-inflammatory neuropeptide used as a nasal spray in the CIRS mold-illness community, the Shoemaker protocol. Its immune-regulating biology is real, and inhaled VIP reduced lung inflammation in a small sarcoidosis trial. But for CIRS specifically the human evidence is weak, largely self-published, and not independently controlled. It is not approved.

Evidence tier: Tier 2 for VIP's immune biology and the sarcoidosis trial; Tier 4 for CIRS-specific nasal-spray claims. Educational content, not medical advice.

The key points:

• An anti-inflammatory neuropeptide — VIP genuinely regulates immune responses and Tregs
• Sarcoidosis signal — a small Phase 2 trial found inhaled VIP reduced lung inflammation
• CIRS use is community-driven — the "Shoemaker protocol," with weak, self-published evidence
• Not an approved therapy — VIP nasal spray is compounded/gray-market, not FDA-approved for CIRS

For the broader topic, see peptides for immune and gut health.

What is VIP, and what does it do?

Evidence tier: 2 — established immunology.

VIP — vasoactive intestinal peptide — is a 28-amino-acid neuropeptide found throughout the nervous system and gut. Beyond its original roles (vasodilation, secretion), it turns out to be a potent anti-inflammatory and immunoregulatory signal. VIP dampens pro-inflammatory cytokines like TNF, IL-6, and IL-12 from macrophages and dendritic cells, shifts immune balance away from inflammatory Th1 responses, and helps induce regulatory T cells (Tregs) that suppress excessive immune activity (Delgado & Ganea, VIP immune functions review, PMID 22139413; VIP innate-immunity review, PMC2730848).

That biology is genuinely well-established, and it's the legitimate scientific foundation people point to when they discuss VIP therapeutically. Because VIP calms overactive immune responses, it's been explored across autoimmune and inflammatory conditions in preclinical models. The important distinction — and the one this article keeps returning to — is between VIP's proven immune biology (strong) and the specific clinical claims made for VIP nasal spray in conditions like CIRS (weak). A real, interesting mechanism is not the same as demonstrated benefit for a particular illness, and conflating the two is where a lot of peptide hype comes from.

What is CIRS and the Shoemaker protocol?

Evidence tier: 3 — a contested clinical framework.

CIRS — Chronic Inflammatory Response Syndrome — is a framework popularized by Dr. Ritchie Shoemaker to describe a persistent, multi-system inflammatory illness attributed to biotoxin exposure, most commonly from water-damaged buildings and mold. In this model, susceptible people (often described via specific HLA genetics) fail to clear biotoxins, producing a self-perpetuating inflammatory state with symptoms spanning fatigue, cognitive difficulty ("brain fog"), and many others. The Shoemaker protocol is a multi-step treatment sequence — remove exposure, bind toxins, correct a cascade of inflammatory markers — with VIP nasal spray positioned as one of the final steps, intended to "reset" the remaining immune and hormonal abnormalities.

It's important to be candid: CIRS is a contested diagnosis. It is not a universally accepted clinical entity, much of its supporting literature is self-published or appears in lower-tier venues rather than in independent, peer-reviewed, controlled trials, and mainstream bodies have not adopted it as a standard diagnosis. That doesn't mean patients aren't genuinely suffering — chronic post-mold or post-exposure symptoms can be real and debilitating — but it does mean the framework and its treatments, including VIP nasal spray, sit outside established evidence-based medicine. Anyone evaluating VIP for CIRS should understand they're looking at a community-driven protocol, not a validated therapy, and read the mechanism claims with that in mind.

Does the human evidence support VIP nasal spray for CIRS?

Evidence tier: 4 — weak, largely uncontrolled CIRS-specific data.

Honestly assessed, no — not to a standard that would qualify as good evidence. The main CIRS-specific support for VIP comes from work by Shoemaker and colleagues reporting that intranasal VIP corrected various inflammatory and proteomic markers and even gray-matter changes in CIRS patients. But that work is largely self-published, mostly uncontrolled (or single-arm/observational), and not independently replicated in rigorous randomized trials. Reports of "unmatched safety in thousands of patients" are registry-style claims, not the kind of blinded, placebo-controlled data that establish efficacy — and without a control group, symptom improvement can't be separated from natural recovery, expectation effects, or the other simultaneous protocol steps.

So the fair verdict is a mechanism-plausible, evidence-weak intervention. VIP could plausibly help calm inflammation given its biology, but plausibility is not proof, and the CIRS-specific human data don't currently support strong claims of benefit. This is a recurring pattern in the immune-and-gut peptide space, and it's exactly the kind of situation our evidence-tier framework is built for: interesting biology and enthusiastic community reports do not, on their own, clear the bar for a validated treatment. If VIP nasal spray works for CIRS, that remains to be demonstrated in controlled research; treat current claims as hypotheses.

Where does VIP have real trial evidence — pulmonary sarcoidosis?

Evidence tier: 2 — a small human Phase 2 trial.

The strongest human evidence for inhaled VIP comes not from CIRS but from pulmonary sarcoidosis — an inflammatory lung disease. In an open-label Phase 2 study, 20 patients with active sarcoidosis inhaled nebulized VIP for 4 weeks; the treatment was well tolerated and significantly reduced TNF-α production by immune cells from bronchoalveolar lavage while increasing regulatory T-cell numbers (Prasse et al. 2010, Am J Respir Crit Care Med, doi:10.1164/rccm.200909-1451OC). This is a real, independent, peer-reviewed demonstration that inhaled VIP can exert anti-inflammatory, immunoregulatory effects in humans — consistent with the mechanism described above.

Two caveats keep this honest. First, it's a small (n=20), open-label study measuring biomarker and immune-cell changes over a short window — a genuine but early signal, not proof of durable clinical benefit, and it hasn't translated into an approved VIP inhalation therapy. Second, and crucially, sarcoidosis is not CIRS. Evidence that inhaled VIP dampens lung inflammation in a defined, biopsy-proven disease does not automatically transfer to a contested, differently-defined syndrome. The sarcoidosis trial is the best reason to take VIP's therapeutic immunology seriously; it is not, by itself, evidence that VIP nasal spray treats mold illness. Keeping those two things separate is the single most useful thing to take away here.

Should you try VIP nasal spray?

Evidence tier: 2 — safety and sourcing judgment.

For most people, this is a "proceed only with a knowledgeable clinician, and with clear eyes" situation rather than a flat yes or no. VIP nasal spray is not an FDA-approved product — in practice it's obtained via compounding pharmacies (often on the prescription of CIRS-oriented practitioners) or, worse, as a gray-market research peptide with the usual authenticity, purity, and sterility risks (spotting counterfeit and gray-market peptides). VIP is generally described as well tolerated, but "well tolerated in uncontrolled reports" is not the same as a fully characterized safety profile, and self-sourcing an intranasal peptide bypasses the diagnostic workup that should precede any such treatment.

The honest bottom-line advice: if you're pursuing VIP for suspected mold illness, do it through a qualified clinician who can evaluate whether your symptoms have another, treatable explanation — and understand that you'd be trying an evidence-weak, off-label intervention, not a proven cure. The legitimate takeaways are that VIP is a real anti-inflammatory neuropeptide with promising early human data in sarcoidosis, and that its CIRS use is community-driven and under-evidenced. Both can be true at once. For where VIP fits among better-studied options, see our overview of peptides for immune and gut health.

Limitations

This is educational content, not medical advice.

• CIRS is a contested diagnosis not universally accepted in mainstream medicine.
• CIRS-specific VIP evidence is weak — largely self-published, uncontrolled, and not independently replicated.
• The sarcoidosis trial is small and open-label (n=20) — a real but early biomarker signal, not proof of clinical cure.
• VIP nasal spray is not FDA-approved — it's compounded or gray-market, with sourcing risks.
• Sarcoidosis is not CIRS — evidence in one does not transfer to the other.
• Marko Maal, MSc Pharmacy reviewed this article. Reviewer attribution does not constitute a doctor-patient relationship.

The bottom line

VIP (vasoactive intestinal peptide) is a genuine anti-inflammatory neuropeptide — it calms pro-inflammatory cytokines and promotes regulatory T cells, and a small Phase 2 trial showed inhaled VIP reduced lung inflammation in sarcoidosis. That's real, independently published science. But the popular use of VIP nasal spray is within the CIRS / mold-illness "Shoemaker protocol," where the diagnosis itself is contested and the VIP-specific human evidence is weak, largely self-published, and uncontrolled. VIP nasal spray is not FDA-approved and is obtained via compounding or the gray market. The intellectually honest position holds two things at once: VIP's immune biology is promising and its sarcoidosis data are legitimate, while its CIRS-specific claims are under-evidenced and should be treated as hypotheses. If you pursue it, do so through a qualified clinician and with realistic expectations.

Related on this site

• Peptides for immune and gut health
• Longevity peptide stacks — evidence debunk
• Spotting counterfeit peptides
• Our evidence-tier framework
• Peptide evidence grades

References

• Prasse A, et al. 2010. Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis. Am J Respir Crit Care Med 182(4):540–548. doi:10.1164/rccm.200909-1451OC — the small Phase 2 human inhaled-VIP trial.
• Delgado M, Ganea D. 2013. Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions. Amino Acids. PMID 22139413 — VIP immune biology and Treg induction.
• Gonzalez-Rey E, et al. Immunomodulation of innate immune responses by vasoactive intestinal peptide (VIP): therapeutic potential in inflammatory disease. PMC. PMC2730848 — VIP anti-inflammatory mechanism.